Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes
Clinical trial NCT03147404 · COMPLETED
Trial details
- NCT number
- NCT03147404
- Sponsor
- Samsung Medical Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-28
- Primary completion
- 2019-07-22
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.